Product Information
RISEDRONATE SODIUM 35 MG TAB is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $1.5981 per EA under NDC 00093309844. Its NADAC has been published 572 times since Oct 21, 2015.
FDA first approved this application on Oct 5, 2007. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
35 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093309844
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
RISEDRONATE SODIUM MONOHYDRATEApproval Type
Generic (ANDA)
FDA Application
ANDA077132FDA Approved
10/5/2007
TE Code
AB
On Market Since
6/1/2015
Pharmacological Classes
Price Statistics
The NADAC for RISEDRONATE SODIUM 35 MG TAB has been published 572 times since Oct 21, 2015, and over the history we have for it it has declined 96.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.5981 per EA |
|---|---|
| All-time high | $43.3459 (Feb 10, 2016) |
| All-time low | $1.1853 (Sep 20, 2023) |
| 52-week high | $2.4340 |
| 52-week low | $1.5981 |
| Median price | $4.1827 |
| Average price | $6.6711 |
| Largest weekly change | +76.8% (Dec 20, 2023) |
| Weeks tracked | 572 |
| Tracking since | Oct 21, 2015 |
Generic Alternatives
The matcher finds 4 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Risedronate Sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Bisphosphonate class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of RISEDRONATE SODIUM 35 MG TAB?
The current National Average Drug Acquisition Cost (NADAC) for RISEDRONATE SODIUM 35 MG TAB, manufactured by Teva Pharmaceuticals USA Inc., is $1.5981 per EA (NDC 00093309844), effective Sep 30, 2026.
How has the price of RISEDRONATE SODIUM 35 MG TAB changed over time?
Over the history we have for it, the NADAC for RISEDRONATE SODIUM 35 MG TAB has declined 96.3%. It has been tracked across 572 weekly CMS publications since Oct 21, 2015.
What are the highest and lowest recorded NADAC prices for RISEDRONATE SODIUM 35 MG TAB?
Since Oct 21, 2015, the NADAC for RISEDRONATE SODIUM 35 MG TAB has ranged from a low of $1.1853 (Sep 20, 2023) to a high of $43.3459 (Feb 10, 2016), with a median of $4.1827 per EA.
Are there cheaper alternatives to RISEDRONATE SODIUM 35 MG TAB?
4 manufacturers publish a NADAC-priced product with the same active ingredient and strength as RISEDRONATE SODIUM 35 MG TAB in a comparable dosage form, but none are currently priced below it.
Who manufactures RISEDRONATE SODIUM 35 MG TAB?
RISEDRONATE SODIUM 35 MG TAB (NDC 00093309844) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.